{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"8.7","value":"4.7"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"12.4","value":"5.2"},{"groupId":"OG002","lowerLimit":"4.4","upperLimit":"20.3","value":"10"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"15.4","value":"0"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"21.8","value":"4.8"},{"groupId":"OG005","lowerLimit":"0.9","upperLimit":"16.1","value":"4.9"},{"groupId":"OG006","lowerLimit":"0.2","upperLimit":"21.8","value":"4.8"},{"groupId":"OG007","lowerLimit":"13.1","upperLimit":"32.4","value":"21.7"},{"groupId":"OG008","lowerLimit":"6.0","upperLimit":"25.7","value":"13.6"},{"groupId":"OG009","lowerLimit":"3.3","upperLimit":"21.8","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"70"},{"groupId":"OG008","value":"45"},{"groupId":"OG009","value":"60"}],"units":"Participants"}],"description":"Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator\n\nThe analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage.\n\nIn the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table below.","dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG000","title":"Lead-in Stage - CRPC"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG001","title":"Lead-in Stage - Melanoma"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG002","title":"Lead-in Stage - NSCLC"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG003","title":"Lead-in Stage - Pancreatic Cancer"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG004","title":"Lead-in Stage - Gastric/GEJ"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG005","title":"Lead-in Stage - Hepatocellular Carcinoma"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG006","title":"Lead-in Stage - SCLC"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG007","title":"Lead-in Stage - Ovarian Cancer"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG008","title":"Lead-in Stage - Metastatic Breast Cancer"},{"description":"cabozantinib, 100 mg, po QD for 12 weeks","id":"OG009","title":"Lead-in Stage - NRE Ovarian Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 44 months","title":"Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only","type":"PRIMARY","unitOfMeasure":"percentage of participants"}